Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
I'm PortAI, I can summarize articles.
Novo Nordisk's oral weight-loss pill, Wegovy, has achieved a record-breaking 500% surge in prescriptions, reaching 20,371 in its second week. This unprecedented growth outpaces competitors like Eli Lilly's Zepbound. The figure may be conservative, as it excludes direct-to-consumer sales and telehealth platforms. With distribution in over 70,000 locations, Novo is poised to dominate the market before Lilly's oral contender arrives in 2026. The GLP-1 market is entering a mass-market phase, potentially reshaping revenue trajectories for both companies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments